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Abstract: Objectives: The aim was to construct 2009 pandemic A/H1N1 influenza VLPs (virus-like particles) and compare the 
immunogenicity and protection efficacy with the commercial Panenza vaccine in BALB/c mouse model. Methods: VLPs derived from 
influenza A/Hong Kong/01/2009 (H1N1) virus were constructed by Bac-to-Bac baculovirus expression system. VLPs were purified by 
sucrose density gradient ultracentrifugation and then characterized by Western blotting analysis and transmission electron microscopy. 
After single dose vaccination with 3 µg of VLPs and equal amount of Panenza vaccine, the immune responses and efficacy of 
protection induced by VLPs were compared with those elicited by the Panenza vaccine in 6-8 weeks old female BALB/c mice. Key 
findings: VLPs could induce higher antibody titer as determined by hemagglutinin inhibition and microneutralization assay. 
Furthermore, we demonstrated that VLPs induced better antibody response to neuraminidase. In addition, VLP vaccinated mice had 
stronger cell-mediated immune response. As a result, our VLPs conferred 100% protection while the Panenza vaccine only conferred 
67% protection. Conclusion: From the results, we concluded that influenza VLPs are highly immunogenic and they are promising to be 
developed as an alternative strategy to vaccine production in order to control the spread of influenza viruses. 
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1. Introduction

 
Influenza A virus belongs to the Orthomyxoviridae 
family and its genome contains 8 negative-sense, single 
stranded RNA segments encoding 11 viral proteins. On 
the viral surface, there are two glycoproteins named 
HA (hemagglutinin) and NA (neuraminidase). The 
structural matrix protein (M1) is the most abundant 
which is found underneath the lipid membrane. In 
April, 2009 CDC of the United States of America 
announced the detection of a novel strain of influenza 
virus in humans [1]. This novel virus transmitted 
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rapidly among humans throughout the world, and on 
May 1st, Hong Kong declared a state of health 
emergency following the first confirmed case of swine 
influenza A H1N1 flu in the territory. On June 11th, the 
World Health Organization raised the worldwide 
pandemic alert level into phase 6 [2]. 
Vaccination is widely considered to be one of the 
most effective preventive strategies for the control of 
seasonal as well as pandemic influenza viruses. The 
current influenza vaccine is usually prepared from 
virus that is grown in embryonated chicken eggs. The 
virus is isolated from the allantoic fluids and then 
inactivated with formaldehyde or ß-propiolactone. 
Alternatively, the purified virus is treated with 
detergent for “split” or “subunit” vaccine formulation 
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[3]. VLPs (Influenza virus like particles) are being 
developed as a new generation of non-egg based cell 
culture-derived vaccine against influenza infection 
during a pandemic threat [4]. This new generation 
vaccine has several advantages over the traditional 
egg-based strategies, especially in its high yield and 
short production time [5]. Several laboratories have 
successfully constructed influenza VLPs [6-13], 
however, there has been no report comparing the 
immunogenicity between VLPs with the commercially 
available vaccine. To afford a better understanding of 
VLPs’ immunogenic efficacy, we constructed VLPs 
derived from an influenza A (H1N1) 2009 virus and 
then made a comparison on induction of immune 
responses and protection efficacy with the  
commercial Panenza inactivated vaccine for the first 
time in mice.  
2. Materials and Methods  
2.1 Recombinant Plasmid Construction 
Viral RNA was extracted from influenza A/Hong 
Kong/01/2009 (H1N1) (HK/01) virus isolate according 
to the manufacturer’s instructions (RNeasy Mini 
Handbook, QIAGEN) and cDNA was synthesized by 
influenza unit 12 primer and superscript II reverse 
transcriptase (Invitrogen). Segment PCR of HA and 
NA and full length of M1 PCR were then conducted 
using primers for the synthesis of the HA, NA, and M1 
listed in Tables 1-3, respectively and cDNA fragments 
were then cloned into PCR2.1-TOPO vector 
(Invitrogen). The nucleotide sequences of the HA, NA, 
and M1 genes were identical to the online published 
sequences (GenBank GQ168606.1, GQ457486.1 and 
FJ966954).  
The full length of HA gene was cloned as a SalI-NotI 
DNA fragment downstream of the AcMNPV 
polyhedrin promoter within pFastBac1 transfer vector 
(Invitrogen). The full length of NA and M1 genes were 
cloned as EcoRI-XhoI DNA fragments into the same 
enzyme digested pFastBac1 plasmid. The three 
resulting baculovirus transfer plasmids were 
designated pHA, pNA, and pM1, located downstream 
of the AcMNPV polyhedrin promoter and upstream of 
the SV40 polyadenylation signal. Then pNA was 
digested with SnaBI and HpaI, and the fragment was 
ligated into the HpaI site of pHA, which resulted the 
 
Table 1  Primers used for HA gene amplification.  
Primer name Sequence (5'--3') 
F-VLP-HA-F ACGCGTCGACATGAAGGCAATACTAGTAG 
F-VLP-HA-MR TCTAGAAGGTTTACAGAGTGTG 
F-VLP-HA-MF CACACTCTGTAAACCTTCTAGA 
F-VLP-HA-R ACGCGCGGCCGCTTAAATACATATTCTACACTG 
The underlined nucleotides indicate recognition sites of SalI and NotI.  
 
Table 2  Primers used for NA gene amplification.  
Primer name Sequence (5'--3') 
F-VLP-NA-F CCGGAATTCATGAATCCAAACCAAAAGAT 
F-VLP-NA-MR GCTGATGTTTACATATGTCTG 
F-VLP-NA-MF CAGACATATGTAAACATCAGC 
F-VLP-NA-R    CGCCGCTCGAGTTACTTGTCAATGGTAAATGGCA 
The underlined nucleotides indicate recognition sites of EcoRI and XhoI.  
 
Table 3  Primers used for M1 gene amplification.  
Primer name Sequence (5'--3') 
F-VLP-M1-F CCGGAATTCATGAGTCTTCTAACCGAGG 
F-VLP-M1-R CCGCCGCTCGAGTCACTTGAATCGCTGCATCTGCAC 
The underlined nucleotides indicated recognition sites of EcoRI and XhoI.  
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pHANA recombinant DNA. Then the fragment of pM1 
digested with SnaBI and AvrII was ligated into 
pHANA fragment digested with HpaI and AvrII, thus 
yielding the recombinant plasmid pHANAM1. 
2.2 Generation of Recombinant Baculoviruses 
The recombinant baculoviruses were generated by 
Bac-to-Bac baculovirus expression system 
(Invitrogen). Briefly, the plasmid pHANAM1 was 
transformed into E. coli DH10Bac competent cells 
(Invitrogen). The recombinant bacmid DNA was 
extracted and transfected into Spodoptera frugiperda 
(Sf9) insect cells for recombinant baculovirus 
packaging with Lipofectamine 2000 reagent 
(Invitrogen). After 3 days, the recombinant 
baculovirus in the supernatant was collected as P1 
viral stock and further amplified into P2 and P3 viral 
stock. The virus titer of P3 viral stock was determined 
by plaque assay using Sf9 insect cells. 
2.3 VLP Production and Purification 
The Sf9 insect cells were infected with P3 
recombinant baculoviruses (MOI = 3) at a cell density 
of 2 × 10
6
/mL in 200 mL suspension culture. The 
culture supernatant was harvested at 72 h 
post-infection and the VLPs were pelleted by 
ultracentrifugation (Rotor-SW32Ti) and resuspended 
in phosphate-buffered saline (PBS) solution (pH 7.2), 
loaded onto a 20%-60% (w/v) discontinuous sucrose in 
NTE buffer (100 mM NaCl, 10 mM Tris-Cl pH 7.4, 1 
mM EDTA ) and ultracentrifuged (Rotor-SW41Ti). 
Fractions were collected and analyzed by 10% 
polyacrylamide gel electrophoresis and Western blot 
using anti-HA, anti-NA and anti-M1 rabbit polyclonal 
antibodies (Immune technology). Bovine serum 
albumin was used as a standard to quantitate the 
amount of HA protein [14]. Quantitative densitometry 
of proteins stained with coomassie blue was performed 
using the Odyssey application software version 3.1 
(Li-Cor Bioscience). 
 
2.4 Transmission Electron Microscopy 
The fractions containing influenza VLPs were 
collected, negatively stained and then examined by 
transmission electron microscope. For negative 
staining, VLPs were loaded onto plastic carbon-coated 
400-mesh copper grids for 2 min, stained with 1% 
uranyl acetate (pH 6.5) for 2 min and then rinsed gently 
with a few drops of distilled water. The grids were 
wicked dry with filter paper and then observed by 
transmission electron microscope (Philips EM 208s). 
2.5 BALB/c Mice Immunization and Influenza Virus 
Challenge  
Female BALB/c mice at the age of 6-8 weeks were 
used in this study. All of the mice were housed in the 
animal facility in accordance with the animal care 
protocol. The animal studies have been approved by 
the CULATR (Committee on the Use of Live Animals 
in Teaching and Research) of the University of Hong 
Kong. Three groups each consisting of fifteen mice 
were vaccinated on day 0. Mice were anesthetized with 
Phenobarbital and then group 1 were inoculated 
intramuscularly (i.m.) with 3 µg (based on HA content) 
of the commercial Panenza vaccine. Group 2 were 
inoculated with 100 µL VLPs containing the same 
amount of HA protein. The negative control group 3 
received equal volume of PBS. Serum samples were 
taken before inoculation as well as on day 21. On day 
21, 3 mice in each group were sacrificed for spleen 
extraction and the remaining mice were challenged 
intranasally with 10LD50 of mouse adapted influenza 
HK/01 virus [15]. Animals are monitored for daily 
activity after viral challenge. On day 5 post-viral 
challenge, 3 mice in each group were sacrificed for 
lung tissue extraction. Half of the lung was fixed in 10% 
formaldehyde for histological analysis and the other 
half was homogenized for virus titer titration in MDCK 
(Madin-Darby canine kidney) cells by plaque assay. 
The remaining 9 mice in each group were used for the 
calculation of the survival rate. 
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2.6 Histopathologic Examination 
For microscopic evaluation of the pathologic 
changes in the lung tissues, 3 mice in each group were 
sacrificed and the lungs were immediately fixed in 10% 
paraformaldehyde. After fixation, they were embedded 
in paraffin. Sections were made at 4 to 6 µm thickness 
and mounted on slides. Histopathological changes 
caused by influenza virus infection were examined by 
H&E (haematoxylin and eosin) staining under light 
microscope. 
2.7 ELISA for Detection of HA Specific IgG Antibodies 
ELISA was conducted to measure the levels of 
HA-specific IgG antibodies in immunized mouse sera. 
Briefly, 96-well plates were coated with 100 ng 
recombinant HA protein per well overnight at 4°C. 
After washing with PBST (PBS containing 0.05% 
Tween 20), the plates were blocked with 200 µL 
blocking buffer overnight at 4°C. After washing, sera 
with serial dilutions were added in triplicates and 
incubated at 37°C for 1 h. After washing, the plates 
were incubated at 37°C for 30 min with a secondary 
goat anti-mouse antibody conjugated with horseradish 
peroxidase (Invitrogen) diluted in diluent buffer. After 
washing, the plates were incubated for 10 min with 
TMB substrate solution. The reaction was stopped by 
1M H2SO4 and the absorbance was then measured at 
450 nm using an ELISA reader (Tecan Group Ltd., 
Switzerland). 
2.8 HI (Hemagglutinin Inhibition) Assay 
The primary assay for determining the amount of 
influenza-specific antibody present in vaccinated 
mouse sera is the HI assay [16]. To inactivate 
non-specific inhibitors, one part of mice sera were 
treated with three parts of RDE II (receptor destroying 
enzyme II) and incubated at 37°C for 18 h. Then the 
RDE II was inactivated at 56°C water bath for 30 min 
and PBS was added, creating 1:10 starting dilution of 
sera. RDE II-treated sera were two-fold serially diluted 
in triplicates in 96-well plates (Greiner bio-one, 
Germany). An equal volume of HK/01 virus, adjusted 
to 8 HAU/50 µL was added into each well. The plates 
were incubated at 37°C for 1 h followed by the addition 
50 µL per well of 0.5% turkey erythrocytes. The plates 
were then incubated at room temperature for 1 h. The 
HI titer was determined as the highest serum dilution 
able to completely inhibit hemagglutination [17].  
2.9 Neutralization Assay 
Mouse sera were tested on MDCK cells for 
neutralization assay according to the WHO manual. 
Briefly, sera were heat inactivated at 56°C for 30 min 
and prepared at 1:10 starting dilution, followed by 
2-fold dilutions. The serially diluted sera were 
incubated with HK/01 virus of 100TCID50/60 µL at 
37°C for 1 h. The 96-well plates with MDCK cells 
were washed with PBS and then 100 µL of neutralized 
samples were transferred to the cell culture plates. 
Virus back titration was also included during the 
procedure. The plates were incubated at 37°C for 3 
days to record cytopathic effect. 
2.10 Quantification of Released Viral RNA by 
Quantitative Real-Time PCR 
MDCK cells were infected with HK/01 virus at high 
MOI of 3. After 2 h infection, the cells were washed 3 
times and the cell culture plates were refilled with fresh 
medium containing different concentrations of 
sera. At 6 h post-infection, both the supernatant and 
cell pellets were collected and viral RNA from 
infectious viruses was quantified by real-time PCR 
with SYBR green PCR Master Mix (Stratagene). 
Primers of real-time PCR for HA gene were: 
HA-Forward: 
5’-CAATAAGACCCAAAGTGAGGG-3’; 
HA-Reverse: 
5’-AATCGTGGACTGGTGTATCTG-3’. β-actin 
primers which were used to detect viral RNA copies in 
the cell pellet were β-actin-Forward: 
5’-GAGACCTTCAACACCCCGG-5’ and β-actin 
Reverse: 5’-ATGTCGCGCACG ATTTCCC-3’. 
Pandemic A/H1N1 2009 Influenza Virus-like Particles Elicited Higher and Broader Immune Responses 
than the Commercial Panenza Vaccine 
  
54 
2.11 ELISpot Assay 
Mouse spleens were extracted for ELISpot assay on 
day 21 before virus challenge. Diluted antibodies for 
IFN-γ, IL-2 and IL-4 were coated onto plates and 
incubated overnight at 4°C. The plates were washed 
thoroughly with PBS and blocked by RPMI-1640 
containing 10% FBS and 1% P/S, and incubated at 
room temperature for more than 2 h. During incubation, 
the splenocytes were isolated and determined as 
previously described [5]. Splenocytes in culture 
medium at 1 × 10
6
/well were stimulated with 
recombinant HA protein (Immune Technology) and 
HA, NA peptides (HAI-535: IYSTVASSL and NAI-73: 
CPISGWAI) (Gl Biochemistry Shanghai Ltd) in 5% 
CO2; 37°C humidified incubator for 36 h. Then the 
plates were washed thoroughly with 0.05% PBST, the 
diluted detection antibodies were added and the plates 
were incubated at room temperature for 2 h. After 
washing, diluted streptavidin peroxidase was added 
into each well and the plates were incubated at room 
temperature for 45 min. The plates were washed again 
and TMB substrate solution was added into each well. 
The spot development was monitored with the help of 
hand-held magnifier and the color development was 
terminated with ddH2O. The plates were air dried and 
spots were counted by an ImmunoSpot ELISPOT 
reader (Cellular Technology Ltd., USA). 
2.12 Statistical Analysis 
Data are presented as the arithmetic mean values of 
two experiments plus SD (standard deviation). 
Statistical significance compared between VLP and 
Panenza vaccinated mouse samples was indicated by 
student’s t-test. 
3. Results and Discussion 
3.1 VLP Generation and Characterization 
The recombinant transfer bacmid DNA was 
successfully constructed containing the three genes of 
HA, NA and M1 and they were within their own 
expression cassette, downstream of the AcMNPV 
polyhedrin promoter and upstream of the SV40 
polyadenylation signal (Fig. 1a). Bovine serum 
albumin was used as a standard to quantitate the 
amount of HA protein in VLPs (Fig. 1b). In order to 
confirm that the influenza HA, NA, and M1 proteins 
were co-expressed, the VLPs fractions were analyzed 
by Western blotting using polyclonal antibodies to the 
three proteins. As shown in Fig. 1c, the three proteins 
were successfully co-expressed. Aliquot of 
concentrated VLPs were negative stained for 
transmission electron microscopy and Fig. 1d shows 
that the three proteins were self-assembled into 
particles with morphology similar to the real virus 
particles. 
3.2 VLP Vaccination Provided Complete Protection 
against Lethal Challenge with HK/01 Virus  
The BALB/c mice were i.n. inoculated with 10 LD50 
of influenza HK/01 virus. All the mice in the negative 
control group which was vaccinated with PBS did not 
survive beyond day 8 after virus challenge, whereas all 
VLP vaccinated mice survived. In contrast, Panenza 
provided incomplete protection against lethal viral 
challenge, in which only about 67% (8/12) mice 
survived (Fig. 2a). The result indicated that VLP 
vaccination could provide more potent protection 
against lethal challenge with HK/01 virus. Virus titer in 
lung tissues was detected by plaque assay and it was 
found that the virus titer in VLP vaccinated mouse 
lungs was significantly lower than that in Panenza 
vaccinated mouse lungs (Fig. 2b). 
3.3 Absence of Histopathological Changes in Lung 
Tissues of Mice Vaccinated with VLPs 
Histopathological changes of mouse lung sections 
collected at 5 days post-challenge were further 
examined by H&E staining (Fig. 3). Compared to the 
uninfected mice (Fig. 3d), lung tissues of PBS injected 
(unvaccinated) mice showed severe inflammation with 
intensive infiltration of lymphocytes and marked tissue  
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Fig. 1  (a) VLP expression cassette. Indicated are the polyhedrin promoter (PPH), polyadenylation signal (p(A)), Tn7 regions, 
gentamicin resistance gene (Gm), and HA, hemagglutinin; NA, neuraminidase; M1, matrix 1 genes; (b) SDS-PAGE of purified 
VLPs stained with gel code reagent. Lane 1, Amersham full-range rainbow molecular weight marker; lanes 2-7, BSA 6 µg, 5 µg, 
4 µg, 3 µg, 2 µg, 1 µg; lanes 8-9, 20 µL, 10 µL VLPs; (c) Western blot analysis of VLPs for HA, NA and M1 proteins; (d) 
Transmission electron micrograph of negatively stained VLPs (x 39,000).  
 
damage (Fig. 3c). The lung sections of the mice 
vaccinated with Panenza exhibited some level of 
inflammatory responses, which were evidenced by 
lymphocyte infiltration in some area of the lung tissues, 
but no obvious tissue damage was observed (Fig. 3a). 
In contrast, no histopathological changes were found in 
lung tissues of the mice vaccinated with VLPs (Fig. 
3b). 
3.4 VLP Vaccination Induced Higher Levels of 
Protective Antibodies 
To understand the underlined mechanism as to why 
VLP vaccination could provide more potent protection 
against the lethal challenge of the virus, serial assays 
were performed. As shown in Fig. 4a, the titer of 
HA-specific IgG antibody was much higher in VLP 
vaccinated group than that in Panenza vaccinated 
group. HI assay is considered to be the gold standard to 
evaluate the immunogenic efficiency in influenza 
vaccine studies, with an HI titer over 40 is considered 
as a representative marker for protection. While from 
Fig. 4b, the HI titer in Panenza vaccinated group was 
only around 20 which was not high enough to provide 
potent protection. It is possible that VLPs are more 
immunogenic over the clinical Panenza vaccine 
because VLPs contain multiple copies of HA antigens 
presented in an organized array, thus allowing better 
activation of the immune responses. Neutralization 
antibody plays an important role in protecting against 
foreign antigens. Normally, neutralizing antibody titer 
reaching 20-40 may provide partial protection against 
lethal viral challenge, while it may provide complete 
protection against lethal viral infection when 
neutralizing antibody titer is over 40. From Fig. 4c, the 
neutralization titer in Panenza vaccinated group was 
only 20 which was not high enough to confer complete 
protection. However the neutralization titer in VLP 
vaccinated group reached 80 which was high enough to 
provide potent protection in mice. 
3.5 VLP Vaccination Induced Higher Levels of 
Antibodies which Inhibited Virus Release from 
Infected MDCK Cells 
It has been reported that NA vaccination can induce 
antibodies which may inhibit influenza virus release 
from the  infected cells  [18, 19].  The presence of NA 
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Fig. 2  Protection efficacy in BALB/c mice. On day 22 after 
vaccination, mice were challenged with 10LD50 of influenza 
HK/01 virus. 5 days later, three mice in each group were 
sacrificed and the lungs were extracted for virus titer 
determination. The remaining 9 mice in each group were 
monitored for 20 days for survival rate calculation. (a) 
Mouse survival rate. Virus titer in lungs was determined by 
(b) plaque assay 5 days after lethal virus challenge. 
Statistical significance compared among VLP and Panenza 
vaccinated mice was indicated by student’s t-test. 
 
antibodies were verified by testing whether the sera 
from the vaccinated mice could inhibit virus release 
from infected cells. The serum samples were added to 
the cell cultures after the cells have been infected with 
high MOI (MOI = 3) of virus. The culture supernatant 
and cell pellets were collected at 6 h post-infection and 
the viral RNA copies were determined by real-time 
PCR. Viral RNA copies in cell pellets of all cultures 
showed similar levels (Figure not shown). Viral RNA 
copies in the culture supernatant in the presence of 20 
folds diluted serum samples from mice vaccinated with  
 
 
Fig. 3  Detection of histopathological changes in lung 
tissues after lethal challenge of HK/01 virus. On day 5 
post-viral challenge, 3 mice in each group were sacrificed for 
lung tissue extraction. Lung tissues were collected from mice 
vaccinated with (a) Panenza vaccine; (b) VLP and (c) PBS 
control at 5 days post-virus challenge; (d) Lung section from 
uninfected normal mouse was included as control. 
Histopathological changes were detected by H&E staining.  
 
VLP and Panenza vaccine were about 10 folds and 2 
folds lower, respectively, than in the presence of sera 
from the mice vaccinated with the PBS control (Fig. 5). 
The results suggested that mice vaccinated with VLPs 
elicited higher levels of neutralizing NA antibodies 
than in those vaccinated with the Panenza vaccine. 
3.6 VLP Vaccination Evoked Strong Cell-Mediated 
Immunity in Mice  
The other important protective factors against viral 
infections that potentially induced by vaccination are 
cell-mediated immune responses [19, 20]. Thus, we 
further evaluated viral specific T help cell and CTL 
responses in the vaccinated mouse spleens (Fig. 6). The 
results showed that VLP vaccination indeed induced 
significantly higher levels of HA specific IL-2 and 
IFN-γ secreting Th1 cells than that of Panenza 
vaccination. Importantly, VLP vaccination elicited 
significantly higher levels of HA and NA specific CTL 
responses. T cell responses, particularly CTL responses, 
are very important in limiting viral infection and 
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Fig. 4  Antibody responses. On day 21, mouse sera in all 
three groups vaccinated with Panenza, VLP and PBS were 
collected. (a) IgG titer; OD (Optical densities) were read at 
450 nm; (b) HI titer and (c) Neutralization antibody titer, 
were determined. Results are expressed as the arithmetic 
means ± SD (n = 3). Statistical significance compared 
between samples from VLP and Panenza vaccinated mice 
was indicated by student’s t-test.  
 
response to the virus clearance [21]. Thus, the results 
indicated that high levels of T cell responses evoked by 
VLP vaccination should play a key role, at least in  
part, in the potent protection against lethal viral 
infection. 
 
Fig. 5  Detection of inhibitory effect of vaccinated mouse 
sera to the virus release. MDCK cells were infected with 
HK/01 virus at MOI of 3. Mouse sera were added to the 
culture supernatants at 2 h post-infection, the supernatants 
were collected at 6 h post-infection and the viral RNA copies 
were measured by real-time PCR. The results are expressed 
as relative viral RNA copies ±SD.  
 
 
Fig. 6  Detection of specific T helper cell and CTL 
responses in vaccinated mice. Splenocytes were collected 21 
days post-vaccination. Splenocytes (1 × 106) were stimulated 
with rHA (for T help cells), HA1-535 and NA1-73 (both for 
CTLs). Influenza HA specific IFN-γ, IL-2 and IL-4 
screening T helper cells, HA1-535 and NA1-73 specific 
IFN-γ and IL-2 producing CTLs were detected by ELISpot. 
The results are presented as the mean values of two 
experiments ±SD. Statistical significance (**P < 0.05) 
compared among VLP and Panenza vaccinated mice was 
indicated by student’s t-test.  
 
4. Conclusions 
In this study, the immune responses and efficacy of 
protection induced by VLPs were compared with those 
elicited by the commercial Panenza vaccine in female 
BALB/c mice for the first time. Our results indicate 
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that VLPs are highly immunogenic and they can induce 
higher and broader immune responses than the 
clinically used Panenza vaccine, which reinforce that 
influenza vaccine using VLPs is quite a promising 
alternative in the future. 
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